@article{45ae367796964010bf6316ad64c7efef,
title = "In reply",
author = "Beer, {Tomasz M.} and Vinay Prasad",
note = "Funding Information: Conflict of Interest Disclosures: Dr Beer reports receiving research funding from Astellas, Boehringer Ingelheim, Bristol-Myers Squibb, Dendreon, Janssen Research & Development, Medivation, OncoGenex, Sotio, and Theraclone Sciences; receiving consulting fees from AbbVie, AstraZeneca, Churchill Pharmaceuticals, Clovis Oncology, Dendreon, Janssen Biotech, Janssen Oncology, Janssen Research & Development, Johnson & Johnson, Janssen Japan, and F. Hoffmann-La Roche; and holding stock in Salarius Pharmaceuticals. No other disclosures are reported.",
year = "2017",
month = nov,
doi = "10.1001/jamaoncol.2017.2349",
language = "English (US)",
volume = "3",
pages = "1588--1589",
journal = "JAMA Oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "11",
}